

# FibroGen Inc

Ticker: FGEN

Country: US

Currency: USD Exchange: NSQ

Industry: Biotechnology & Medical Research

Buy

	Current (\$)	1W (\$)	1W (%)	LW (\$)
Close price	25.45	2.14 ▲	9.18 %	23.31
Target price	37.80	0.00	0.00 %	37.80

FibroGen, Inc. is a research-based, biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic agents. Its lead product candidate is roxadustat, or FG-4592 is an oral small molecule inhibitor of hypoxia inducible factor-prolyl hydroxylase (HIF-PHs), in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD). The Company's second product candidate, FG-3019, is a monoclonal antibody in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer and liver fibrosis. Roxadustat is a HIF-PH inhibitor that acts by stimulating the body's natural pathway of erythropoiesis, or red blood cell production. FG-5200 is a corneal implant. Its product FG-3019 blocks FG-3019 blocks CTGF (CTGF). FG-6874 is a HIF-PH inhibitor. FG-8205 is in preclinical evaluation for use as a cardioprotective agent to prevent the onset of heart failure following a heart attack.



Ratios	This week	Last week
Close price	25.45 ▲	23.31
High	25.66 ▲	24.29
Low	23.66 ▲	22.94
Beta	-	-
Market cap	1,541 M ▲	1,411 M
Volume	-	-
P/S ratio	11.20 x ▲	10.25 x
P/E ratio	-	-
P/B ratio	6.78 x ▲	6.21 x
DPS yield	-	-
EV/EBITDA	-	-

(Unit : \$)

## Headline

Created at	Type	Title
none		

## Rating and Target Price

(Unit : \$)

Target price	Last week	Weight
<b>Buy</b>		
<b>37.80</b>		
Valuation analysis	-	-
Target price	-	-
Analysts consensus	Outperform	Outperform
Target price	37.80	37.80 +100 %
Retail consensus	-	-
Target price	-	-

## Analyst projections(2015)


(Unit : \$)

	Consensus	vs.LFY	High	Low	Participants
Revenue	211 M	+53.36 %	230 M	181 M	6
EPS	-0.81	+74.28 %	-0.08	-1.38	6
DPS	0.00	-	0.00	0.00	1

## Income Statement Summary

(Unit : \$)

	2012	2013	2014
Revenue	65 M	102 M	137 M
Operating income	-27 M	-7 M	-50 M
Net income	-32 M	-14 M	-59 M



The company profile, other company-related information, analysts' opinion and projections in this Report are supplied by Thomson Reuters. This Report is intended to be used for information and reference purposes only, and does not constitute a solicitation, or an offer to make an investment in, or to purchase or sell, any specific investment products. The information in this Report may contain projections, opinions, assumptions, estimates and forecasts relating to future business performance and events. Minkabu Group makes no warranty regarding the accuracy or reliability of such projections, opinions, assumptions, estimates or forecasts, and has no liability for any damage of any kind arising out of reliance on such information. For more details, please refer to the Disclaimer on the last page of this Report.

# FibroGen Inc

Ticker: FGEN Exchange: NSQ

## Valuation analysis


Analysis is excluded.

## Analysts consensus

<b>Outperform</b>	Target price	Potential
	37.80 \$	+48.52 %

(Last week)

<b>Outperform</b>	Target price
	37.80 \$



## Valuation

### Based on analyst projections

	Consensus	Low	High	Domestic(0)	Global(0)
PSR	7.30 x	6.29 x	7.96 x	149.94 x	128.55 x
PER	-31.22 x	-318.12 x	-18.44 x	30.15 x	54.88 x

### Based on last year's results

	FibroGen Inc	Domestic(0)	Global(0)
P/S ratio	11.20 x	13.59 x	14.29 x
P/E ratio	-	32.91 x	63.85 x

The company profile, other company-related information, analysts' opinion and projections in this Report are supplied by Thomson Reuters. This Report is intended to be used for information and reference purposes only, and does not constitute a solicitation, or an offer to make an investment in, or to purchase or sell, any specific investment products. The information in this Report may contain projections, opinions, assumptions, estimates and forecasts relating to future business performance and events. Minkabu Group makes no warranty regarding the accuracy or reliability of such projections, opinions, assumptions, estimates or forecasts, and has no liability for any damage of any kind arising out of reliance on such information. For more details, please refer to the Disclaimer on the last page of this Report.

# FibroGen Inc

Ticker: FGEN Exchange: NSQ

## Industry average (domestic): Biotechnology & Medical Research w/Top 3 market cap


### Rating & Valuation

(Unit : \$)

		FibroGen Inc	Gilead Sciences Inc [GILD/US]	Amgen Inc [AMGN/US]	Celgene Corp [CELG/US]	Domestic(Ø)
Close price		25.45	108.34	160.46	116.74	-
Valuation analysis	Rating	-	Undervalued	Undervalued	Overvalued	-
	Target price	-	119.70	165.25	109.53	-
	Potential	-	+10.48 %	+2.98 %	-6.16 %	-
Analysts consensus	Rating	Outperform	Outperform	Outperform	Outperform	-
	Target price	37.80	125.31	186.33	146.12	-
	Potential	+48.52 %	+15.66 %	+16.12 %	+25.17 %	-
Retail consensus	Rating	-	-	-	-	-
	Target price	-	-	-	-	-
	Potential	-	-	-	-	-
Market cap		1,541 M	156,137 M	121,039 M	91,717 M	834 M
EnterpriseValue		1,474 M	158,413 M	124,728 M	91,042 M	826 M
P/E ratio	last FY (norm.)	-	14.74 x	22.43 x	47.71 x	32.91 x
	projected	-31.22 x	8.87 x	15.90 x	24.15 x	30.15 x
PSR	last FY	11.20 x	6.27 x	6.03 x	11.95 x	13.59 x
	projected	7.30 x	4.85 x	5.59 x	9.93 x	149.94 x
EV/EBITDA(LFT)		-32.32 x	9.70 x	14.40 x	30.95 x	23.99 x

### Fundamentals

		FibroGen Inc	Gilead Sciences Inc	Amgen Inc	Celgene Corp	Domestic(Ø)
Sales	last FY	137 M	24,890 M	20,063 M	7,670 M	96 M
	projected	211 M	32,130 M	21,619 M	9,234 M	100 M
	vs last FY	+53.36 %	+29.08 %	+7.75 %	+20.39 %	-
Income before tax	last FY	-59 M	14,856 M	5,585 M	2,327 M	165 M
	projected	-47 M	-	-	-	66 M
	vs last FY	-	-	-	-	-
EBITDA(LFY)		-45 M	16,315 M	8,660 M	2,941 M	197 M
Book value(LFY)		221 M	15,426 M	25,778 M	6,524 M	97 M



The company profile, other company-related information, analysts' opinion and projections in this Report are supplied by Thomson Reuters. This Report is intended to be used for information and reference purposes only, and does not constitute a solicitation, or an offer to make an investment in, or to purchase or sell, any specific investment products. The information in this Report may contain projections, opinions, assumptions, estimates and forecasts relating to future business performance and events. Minkabu Group makes no warranty regarding the accuracy or reliability of such projections, opinions, assumptions, estimates or forecasts, and has no liability for any damage of any kind arising out of reliance on such information. For more details, please refer to the Disclaimer on the last page of this Report.

# FibroGen Inc

Ticker: FGEN Exchange: NSQ

## Industry average (worldwide): Biotechnology & Medical Research Market cap Top3


### Rating & Valuation

(Unit : \$)

		FibroGen Inc	Gilead Sciences Inc [GILD/US]	Amgen Inc [AMGN/US]	Celgene Corp [CELG/US]	Global(Ø)
Close price		25.45	108.34	160.46	116.74	-
Valuation analysis	Rating	-	Undervalued	Undervalued	Overvalued	-
	Target price	-	119.70	165.25	109.53	-
	Potential	-	+10.48 %	+2.98 %	-6.16 %	-
Analysts consensus	Rating	Outperform	Outperform	Outperform	Outperform	-
	Target price	37.80	125.31	186.33	146.12	-
	Potential	+48.52 %	+15.66 %	+16.12 %	+25.17 %	-
Retail consensus	Rating	-	-	-	-	-
	Target price	-	-	-	-	-
	Potential	-	-	-	-	-
Market cap		1,541 M	156,137 M	121,039 M	91,717 M	760 M
EnterpriseValue		1,474 M	158,413 M	124,728 M	91,042 M	1,924 M
P/E ratio	last FY (norm.)	-	14.74 x	22.43 x	47.71 x	63.85 x
	projected	-31.22 x	8.87 x	15.90 x	24.15 x	54.88 x
PSR	last FY	11.20 x	6.27 x	6.03 x	11.95 x	14.29 x
	projected	7.30 x	4.85 x	5.59 x	9.93 x	128.55 x
EV/EBITDA(LFT)		-32.32 x	9.70 x	14.40 x	30.95 x	40.81 x

### Fundamentals

		FibroGen Inc	Gilead Sciences Inc	Amgen Inc	Celgene Corp	Global(Ø)
Sales	last FY	137 M	24,890 M	20,063 M	7,670 M	90 M
	projected	211 M	32,130 M	21,619 M	9,234 M	87 M
	vs.LFY	+53.36 %	+29.08 %	+7.75 %	+20.39 %	-
Income before tax	last FY	-59 M	14,856 M	5,585 M	2,327 M	115 M
	projected	-47 M	-	-	-	60 M
	vs.LFY	-	-	-	-	-
EBITDA(LFY)		-45 M	16,315 M	8,660 M	2,941 M	130 M
Book value(LFY)		221 M	15,426 M	25,778 M	6,524 M	100 M



The company profile, other company-related information, analysts' opinion and projections in this Report are supplied by Thomson Reuters. This Report is intended to be used for information and reference purposes only, and does not constitute a solicitation, or an offer to make an investment in, or to purchases or sell, any specific investment products. The information in this Report may contain projections, opinions, assumptions, estimates and forecasts relating to future business performance and events. Minkabu Group makes no warranty regarding the accuracy or reliability of such projections, opinions, assumptions, estimates or forecasts, and has no liability for any damage of any kind arising out of reliance on such information. For more details, please refer to the Disclaimer on the last page of this Report.

# FibroGen Inc

Ticker: FGEN Exchange: NSQ

## Financials

### Income statement

(Unit : M\$)

	2012	2013	2014
Revenue	65	102	137
Total revenue	65	102	137
Selling general administrative expenses total	18	24	36
Research and development	74	85	150
Total operating expense	93	110	187
Operating income	-27	-7	-50
Interest income or expense net non operating	-5	-7	-9
Other net	0	0	0
Income before tax	-32	-14	-59
Income tax total	-0	0	0
Income after tax	-32	-14	-59
Net income before extra items	-32	-14	-59
Net income	-32	-14	-59
Diluted net income	-32	-14	-59
Income available to common excl extra items	-32	-14	-59
Income available to common incl extra items	-32	-14	-59
Diluted weighted average shares	55	55	18

### Balance sheet summary

(Unit : M\$)


	2012	2013	2014
Cash	20	27	151
Cash and equivalents	18	48	13
Short term investments	1	46	14
Cash and short term investments	39	122	179
Accounts receivable trade net	8	17	13
Total receivables net	8	17	13
Prepaid expenses	4	3	4
Total current assets	52	143	198
Property plant equipment total gross	156	167	-
Accumulated depreciation total	-33	-38	-
Property plant equipment total net	123	129	132
Long term investments	81	15	144
Other long term assets total	7	8	8
Total assets	265	296	483
Accounts payable	3	1	4
Accrued expenses	14	26	41
Current port of lt debt capital leases	1	1	-
Other current liabilities total	4	8	17
Total current liabilities	23	37	62
Long term debt	17	18	16
Capital lease obligations	93	96	96
Total long term debt	110	114	113
Minority interest bs	27	27	19
Other liabilities total	9	37	66
Total liabilities	171	217	262
Redeemable preferred stock	304	304	-
Additional paid in capital	37	41	546
Retained earnings or accumulated deficit	-247	-262	-322
Other equity total	-0	-3	-3
Total equity	94	79	221
Total liabilities and shareholders equity	265	296	483
Total debt	112	115	113

The company profile, other company-related information, analysts' opinion and projections in this Report are supplied by Thomson Reuters. This Report is intended to be used for information and reference purposes only, and does not constitute a solicitation, or an offer to make an investment in, or to purchase or sell, any specific investment products. The information in this Report may contain projections, opinions, assumptions, estimates and forecasts relating to future business performance and events. Minkabu Group makes no warranty regarding the accuracy or reliability of such projections, opinions, assumptions, estimates or forecasts, and has no liability for any damage of any kind arising out of reliance on such information. For more details, please refer to the Disclaimer on the last page of this Report.

## Cash flow summary

(Unit : M\$)

	2012	2013	2014
Net income starting line	-32	-14	-59
Depreciation depletion	5	5	4
Non cash items	5	3	19
Cash interest paid	0	0	0
Changes in working capital	16	31	58
Cash from operating activities	-5	25	22
Capital expenditures	-0	-6	-8
Other investing cash flow items total	19	17	-99
Cash from investing activities	19	10	-107
Issuance or retirement of stock net	0	0	1
Issuance or retirement of debt net	-0	0	-0
Cash from financing activities	6	0	174
Financing cash flow items	7	0	172
Foreign exchange effects	-0	0	-0
Net change in cash	20	37	89



The company profile, other company-related information, analysts' opinion and projections in this Report are supplied by Thomson Reuters. This Report is intended to be used for information and reference purposes only, and does not constitute a solicitation, or an offer to make an investment in, or to purchases or sell, any specific investment products. The information in this Report may contain projections, opinions, assumptions, estimates and forecasts relating to future business performance and events. Minkabu Group makes no warranty regarding the accuracy or reliability of such projections, opinions, assumptions, estimates or forecasts, and has no liability for any damage of any kind arising out of reliance on such information. For more details, please refer to the Disclaimer on the last page of this Report.

# FibroGen Inc

Ticker: FGEN Exchange: NSQ

## Corporate profile

### Company profile

Business summary	FibroGen, Inc. is a research-based, biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic agents. Its lead product candidate is roxadustat, or FG-4592 is an oral small molecule inhibitor of hypoxia inducible factor-prolyl hydroxylase (HIF-PHs), in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD). The Company's second product candidate, FG-3019, is a monoclonal antibody in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer and liver fibrosis. Roxadustat is a HIF-PH inhibitor that acts by stimulating the body's natural pathway of erythropoiesis, or red blood cell production. FG-5200 is a corneal implant. Its product FG-3019 blocks FG-3019 blocks CTGF (CTGF). FG-6874 is a HIF-PH inhibitor. FG-8205 is in preclinical evaluation for use as a cardioprotective agent to prevent the onset of heart failure following a heart attack.
Financial summary	BRIEF: For the six months ended 30 June 2015, FibroGen Inc revenues increased 27% to \$136.8M. Net income applicable to common stockholders increased 8% to \$10.7M. Revenues reflect License and milestone revenue increase of 22% to \$118.4M, Collaboration services and other revenue increase of 73% to \$18.5M. Net income was partially offset by Research and Development increase of 61% to \$93.4M (expense).
Homepage	<a href="http://www.FibroGen.com">http://www.FibroGen.com</a>
Address	409 Illinois St SAN FRANCISCO CA
Public contact	
Phone number	1-415-9781200
Contact phone number	
Contact email	

### Management

Rank	Name	Position	Since	Age
1	Thomas B. Neff	Chairman of the Board, Chief Executive Officer, Founder		60
2	Pat Cotroneo	Chief Financial Officer, Vice President - Finance	2008	50
3	K Peony Yu	Vice President - Clinical Development	2008-12	52
4	Frank H. Valone	Chief Medical Officer	2008-12	65

On September 30, 2014 FibroGen Inc had 337 Employees.

The company profile, other company-related information, analysts' opinion and projections in this Report are supplied by Thomson Reuters. This Report is intended to be used for information and reference purposes only, and does not constitute a solicitation, or an offer to make an investment in, or to purchase or sell, any specific investment products. The information in this Report may contain projections, opinions, assumptions, estimates and forecasts relating to future business performance and events. Minkabu Group makes no warranty regarding the accuracy or reliability of such projections, opinions, assumptions, estimates or forecasts, and has no liability for any damage of any kind arising out of reliance on such information. For more details, please refer to the Disclaimer on the last page of this Report.

# FibroGen Inc

Ticker: FGEN Exchange: NSQ

## Historical Charts

M3 Chart



Historical data

(Unit : \$)

	High	Low	Volume
2015/08/10 -	25.94	21.36	2,560,947
2015/08/17 -	25.98	22.39	2,548,503
2015/08/24 -	24.62	20.02	1,873,460
2015/08/31 -	24.71	22.16	1,774,263
2015/09/07 -	29.88	23.36	3,462,701
2015/09/14 -	29.86	27.03	3,807,867
2015/09/21 -	29.97	24.51	2,420,106
2015/09/28 -	24.73	20.50	2,858,950
2015/10/05 -	23.00	20.59	1,559,965
2015/10/12 -	22.99	20.04	1,016,203
2015/10/19 -	25.74	21.31	2,521,729
2015/10/26 -	25.04	21.37	1,759,560
During	29.97	20.02	-

Y1 Chart




Historical data

(Unit : \$)

	High	Low	Volume
2014/12/01 -	31.48	20.10	6,213,393
2015/01/01 -	40.59	27.06	3,769,517
2015/02/01 -	32.78	29.33	1,742,743
2015/03/01 -	32.79	28.00	3,521,065
2015/04/01 -	31.99	23.00	2,278,929
2015/05/01 -	24.77	17.04	13,514,515
2015/06/01 -	24.56	16.95	28,569,780
2015/07/01 -	25.46	21.56	7,999,699
2015/08/01 -	25.98	20.02	9,427,842
2015/09/01 -	29.97	21.03	12,845,847
2015/10/01 -	25.74	20.04	7,760,030
During	40.59	16.95	-

Y5 Chart



The company profile, other company-related information, analysts' opinion and projections in this Report are supplied by Thomson Reuters. This Report is intended to be used for information and reference purposes only, and does not constitute a solicitation, or an offer to make an investment in, or to purchases or sell, any specific investment products. The information in this Report may contain projections, opinions, assumptions, estimates and forecasts relating to future business performance and events. Minkabu Group makes no warranty regarding the accuracy or reliability of such projections, opinions, assumptions, estimates or forecasts, and has no liability for any damage of any kind arising out of reliance on such information. For more details, please refer to the Disclaimer on the last page of this Report.



# FibroGen Inc

Ticker: FGEN Exchange: NSQ

## Disclaimer

This Report (this "Report") is prepared by Minkabu, Inc. and its subsidiary, sharewise GmbH (collectively, "Minkabu Group") based on information supplied by a third party service provider, namely Thomson Reuters.

The company profile, other company-related information, analysts' opinions and projections in this Report are supplied by Thomson Reuters. Stock and index prices are supplied by Stock Exchanges of Tradegate Exchange, Euronext, Deutsche Börse AG, BME, Stuttgart Stock Exchange, Tradegate Exchange, BATS CHI-X Europe, London Stock Exchange, NASDAQ Stock Market, Indonesia Stock Exchange, Singapore Exchange, Hong Kong Exchanges and Clearing Limited, Taiwan Stock Exchange, Tokyo Stock Exchange, Nagoya Stock Exchange, Toronto Stock Exchange, Shenzhen Stock Exchange, Shanghai Stock Exchange, SIX Swiss Exchange, BM&FBOVESPA S.A, DotEx. HKEX INFORMATION SERVICES LIMITED, ITS HOLDING COMPANIES AND/OR ANY SUBSIDIARIES OF SUCH HOLDING COMPANIES ENDEAVOUR TO ENSURE THE ACCURACY AND RELIABILITY OF THE INFORMATION PROVIDED BUT DO NOT GUARANTEE ITS ACCURACY OR RELIABILITY AND ACCEPT NO LIABILITY (WHETHER IN TORT OR CONTRACT OR OTHERWISE) FOR ANY LOSS OR DAMAGE ARISING FROM ANY INACCURACIES OR OMISSIONS. Any expressions of opinions by analysts are solely the personal opinions of the authors and contributors to this Report. Minkabu Group is not responsible for accuracy, completeness, reliability or timeliness for these information and opinions, and is not responsible for any errors or omissions therein, and assumes no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of your reliance on such information or the use of this Report.

The information in this Report may contain projections, opinions, assumptions, estimates and forecasts relating to future business performance and events, which are intended as examples only, and do not represent predictions by Minkabu Group about the current or future performance of any company or its securities, or any investment products. Minkabu Group makes no warranty regarding the accuracy or reliability of such projections, opinions, assumptions, estimates or forecasts, and has no liability for any damage of any kind arising out of reliance on such information. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Actual results may differ from those in forward-looking statements as a result of various factors. Minkabu Group is not obligated to update or correct any such information.

This Report does not constitute a recommendation to make an investment in, or to purchase or sell any specific investment products. This Report is not intended to give financial or investment advice. You should conduct your own careful, independent analysis or seek advice from professional advisor as to the suitability of an investment for your needs.

Minkabu Group does not express any opinion on any company or its securities, or any investment products (or any fluctuations in or future performance thereof), and stock price ratings and comments including "Target Price", "Buy", "Sell", or "Hold" are created by an aggregation of opinions from individual investors, or from opinions of analysts of securities companies.

Ratings such as "Overvalued", "Undervalued" or "Fairlyvalued", and "Fair Stock Prices" and others displayed ancillary to ratings are objective facts based on the statistical record, and Minkabu Group does not express any opinion on any company or its securities, or any investment products (or any fluctuations in or future performance thereof) thereby either.

Minkabu Group does not represent or warrant that this Report is appropriate or available for viewing or downloading at any location. You are exclusively responsible for compliance with all applicable local laws and regulations in viewing or downloading this Report.

This Report is intended to be used for information and reference purposes only, and does not constitute a solicitation, or an offer to make an investment in, or to purchase or sell, any specific investment products. Minkabu Group is not a registered broker, dealer, investment advisor, analyst, investment banker or underwriter.

Minkabu Group may hold the securities referred to in this Report including derivative instruments, or may have business relations with the companies discussed herein.

Without prior written consent of Minkabu Group, no reproduction, copy, transmission, transfer, distribution, publication, or any other similar actions of any content of this Report shall be made.